13 research outputs found
Reinforcement–concrete bond behavior: Experimentation in drying conditions and meso-scale modeling
A reappraisal of the Dinantian floras at Oxroad Bay, East Lothian, Scotland. 1. Floristics and the development of whole-plant concepts
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
BACKGROUND: The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown.
METHODS: Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled evaluation of the selected dose. In part 2, we randomly assigned young children (6 months to 5 years of age) in a 3:1 ratio to receive two 25-μg injections of mRNA-1273 or placebo, administered 28 days apart. The primary objectives were to evaluate the safety and reactogenicity of the vaccine and to determine whether the immune response in these children was noninferior to that in young adults (18 to 25 years of age) in a related phase 3 trial. Secondary objectives were to determine the incidences of Covid-19 and severe acute respiratory syndrome coronavirus 2 infection after administration of mRNA-1273 or placebo.
RESULTS: On the basis of safety and immunogenicity results in part 1 of the trial, the 25-μg dose was evaluated in part 2. In part 2, 3040 children 2 to 5 years of age and 1762 children 6 to 23 months of age were randomly assigned to receive two 25-μg injections of mRNA-1273; 1008 children 2 to 5 years of age and 593 children 6 to 23 months of age were randomly assigned to receive placebo. The median duration of follow-up after the second injection was 71 days in the 2-to-5-year-old cohort and 68 days in the 6-to-23-month-old cohort. Adverse events were mainly low-grade and transient, and no new safety concerns were identified. At day 57, neutralizing antibody geometric mean concentrations were 1410 (95% confidence interval [CI], 1272 to 1563) among 2-to-5-year-olds and 1781 (95% CI, 1616 to 1962) among 6-to-23-month-olds, as compared with 1391 (95% CI, 1263 to 1531) among young adults, who had received 100-μg injections of mRNA-1273, findings that met the noninferiority criteria for immune responses for both age cohorts. The estimated vaccine efficacy against Covid-19 was 36.8% (95% CI, 12.5 to 54.0) among 2-to-5-year-olds and 50.6% (95% CI, 21.4 to 68.6) among 6-to-23-month-olds, at a time when B.1.1.529 (omicron) was the predominant circulating variant.
CONCLUSIONS: Two 25-μg doses of the mRNA-1273 vaccine were found to be safe in children 6 months to 5 years of age and elicited immune responses that were noninferior to those in young adults.
(Funded by the Biomedical Advanced Research and Development Authority and National Institute of Allergy and Infectious Diseases; KidCOVE ClinicalTrials.gov number, NCT04796896.)
Genetic structure and diversity of coffee (Coffea) across Africa and the Indian Ocean islands revealed using microsatellites
Which name(s) should be used for Araucaria-likefossil wood? – Results of a poll
Araucarioxylon Kraus is a widely known fossil-genus generally applied to woods similar to that of the extant Araucariaceae. However, since 1905, several researchers have pointed out that this name is an illegitimate junior nomenclatural synonym. At least four generic names are in current use for fossil wood of this type: Agathoxylon Hartig, Araucarioxylon, Dadoxylon Endl. and Dammaroxylon J.Schultze-Motel. This problem of inconsistent nomenclatural application is compounded by the fact that woods of this type represent a wide range of plants including basal pteridosperms, cordaitaleans, glossopterids, primitive conifers, and araucarian conifers, with a fossil record that extends from the Devonian to Holocene. Conservation of Araucarioxylon has been repeatedly suggested but never officially proposed. Since general use is a strong argument for conservation, a poll was conducted amongst fossil wood anatomists in order to canvass current and preferred usage. It was found that the community is divided, with about one-fifth recommending retention of the well-known Araucarioxylon, whereas the majority of others advocated use of the legitimate Agathoxylon. The arguments of the various colleagues who answered the poll are synthesized and discussed. There is clearly little support for conservation of Araucarioxylon. A secondary aspect of the poll tackled the issue as to whether Araucaria-like fossil woods should be either gathered into a unique fossil-genus, or whether two fossil-genera should be recognized, based on the respective presence or absence of axial parenchyma. A majority of colleagues favoured having one fossil-genus only. Agathoxylon can be used legitimately and appears to be the most appropriate name for such woods. However, its original diagnosis must be expanded if those woods lacking axial parenchyma are to be included
Recommended from our members
Risk of COVID-19 after natural infection or vaccinationResearch in context
Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health